The current standard of care for management of DMD associated cardiomyopathy includes the use of generic heart failure therapies with ACE inhibitors, angiotensin receptor blockers, and beta blocker therapies based on few small, clinical studies demonstrating clinical benefit on left ventricular function and survival [46–49]. This evidence concerns the gene ACE and cardiomyopathy.